Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.Steven N. Seyedin, Nataliya Mar, M. Semaan et al.|Journal of Clinical Oncology|2026Cited by 0
Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedodin (EV) plus pembrolizumab (P).Nataliya Mar, Steven N. Seyedin, Dimitrios Stefanoudakis et al.|Journal of Clinical Oncology|2026Cited by 0